[Ip-health] IP on Coronavirus

Baker, Brook b.baker at northeastern.edu
Mon Mar 16 06:32:34 PDT 2020


A super quick count found granted patents in 73 out of 145 countries with pending applications in many others. 

Brook

On 3/15/20, 12:54 PM, "Ip-health on behalf of Duncan Matthews" <ip-health-bounces at lists.keionline.org on behalf of d.n.matthews at qmul.ac.uk> wrote:

    Thanks Ellen, this is very helpful.
    
    Aside from patents, the FDA has issued a new policy for certain labs to begin use of validated Covid-19 diagnostics before the completing review under the Emergency Use Authorization procedure but I cannot find equivalent FDA provisions on products for the treatment of Covid-19.
     
    Does anyone know if there are new FDA provisions to expediate use of a new product (medicine or vaccine) to treat Covid-19?
     
    In Europe the EMA has said it will provide full fee waivers on scientific advice and can issue a conditional market authorisation where the benefits of immediate availability outweigh the risks of less comprehensive data than normally required.
    
    Apologies for cross-posting.
    
    Best,
    
    Duncan
     
    Duncan Matthews
    Professor of Intellectual Property Law
    Director, Queen Mary Intellectual Property Research Institute
    Queen Mary University of London
    
    
    
    On 15/03/2020, 05:51, "Ip-health on behalf of Ellen 't Hoen" <ip-health-bounces at lists.keionline.org on behalf of ellenthoen at medicineslawandpolicy.net> wrote:
    
        
        Dear All,
        
        Thanks for posting this Sean.
        
        It may be of interest to IP-health readers that the Medicines Patent Pool has added patent status information regarding potential treatments of covid-19, including remdesivir, to their patent data base Medspal.
        
        This is what it shows on remdesivir for China and India: https://nam05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medspal.org%2F%3Fkeywords%3DRemdesivir%26country_name%255B%255D%3DChina%26country_name%255B%255D%3DIndia%26page%3D1&data=02%7C01%7Cb.baker%40northeastern.edu%7C4c8794ca79e1477b4ff008d7c9018b73%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637198880779926803&sdata=JR9ZlzKFqy0CeCNOK9up7nId%2FtrXq18MkjZLjtM8UFY%3D&reserved=0
        
        Check out other countries on: medspal.org
        
        No such information on the WIPO medicines patent database Pat-informed yet. 
        
        Kind regards,
        
        Ellen
        
        ————————————————————
        Ellen ‘t Hoen LLM, PhD | Medicines Law & Policy
        https://nam05.safelinks.protection.outlook.com/?url=www.medicineslawandpolicy.org&data=02%7C01%7Cb.baker%40northeastern.edu%7C4c8794ca79e1477b4ff008d7c9018b73%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637198880779926803&sdata=zJfQbkuAUPQFTRgBxGZQvy7VPLYg5u2zAEZbgzRffAA%3D&reserved=0
        Tel.: +31 6 37530700
        E-mail: ellenthoen at medicineslawandpolicy.net
        Twitter: @ellenthoen
        
        
        >> On 14 Mar 2020, at 16:01, Sean Flynn <sflynn at wcl.american.edu> wrote:
        > From Duncan Mathews (who may be on this list too):
        > 
        > IPR Daily<https://nam05.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.iprdaily.com%2Farticle%2Findex%2F15372.html&data=02%7C01%7Cb.baker%40northeastern.edu%7C4c8794ca79e1477b4ff008d7c9018b73%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637198880779926803&sdata=RMVHYCfgWEnbyp3VAu1lup6bWUPui4jKM5YfLN1jWjc%3D&reserved=0>  reports that the Wuhan Institute of Virology filed a patent application on use of  Gilead Sciences’ remdesivir for the treatment of covid-19. Gilead does not seem to a partner on the application.
        > 
        > SNIP
        > The Wuhan Institute submitted the patent application jointly with the Military Medicine Institute of the People’s Liberation Army Academy of Military Science. Researchers with both organizations noted in a paper published in Nature’s Cell Research this week that both remdesivir and chloroquine, used to treat malaria, may be effective in stalling the coronavirus.
        > 
        > “Even if the Wuhan Institute’s application gets authorized, the role is very limited because Gilead still owns the fundamental patent of the drug,” said Zhao Youbin, a Shanghai-based intellectual property attorney at Purplevine IP Service Co. “Any exploitation of the patent must seek approval from Gilead.”
        > 
        > The Wuhan Institute indicated it filed the patent application on January 21, but also noted it would temporarily drop the patent claims if it had the opportunity to collaborate with foreign biopharma companies to battle the epidemic.
        > 
        > --- snip
        > 
        > 
        > _______________________________________________
        > Ip-health mailing list
        > Ip-health at lists.keionline.org
        > https://nam05.safelinks.protection.outlook.com/?url=http%3A%2F%2Flists.keionline.org%2Fmailman%2Flistinfo%2Fip-health_lists.keionline.org&data=02%7C01%7Cb.baker%40northeastern.edu%7C4c8794ca79e1477b4ff008d7c9018b73%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637198880779936798&sdata=bNa2xlRVpEfgjiPEPy73rK9lp7YJtE%2BMP7OopRU1MZk%3D&reserved=0
        _______________________________________________
        Ip-health mailing list
        Ip-health at lists.keionline.org
        https://nam05.safelinks.protection.outlook.com/?url=http%3A%2F%2Flists.keionline.org%2Fmailman%2Flistinfo%2Fip-health_lists.keionline.org&data=02%7C01%7Cb.baker%40northeastern.edu%7C4c8794ca79e1477b4ff008d7c9018b73%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637198880779936798&sdata=bNa2xlRVpEfgjiPEPy73rK9lp7YJtE%2BMP7OopRU1MZk%3D&reserved=0
        
    
    _______________________________________________
    Ip-health mailing list
    Ip-health at lists.keionline.org
    https://nam05.safelinks.protection.outlook.com/?url=http%3A%2F%2Flists.keionline.org%2Fmailman%2Flistinfo%2Fip-health_lists.keionline.org&data=02%7C01%7Cb.baker%40northeastern.edu%7C4c8794ca79e1477b4ff008d7c9018b73%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637198880779936798&sdata=bNa2xlRVpEfgjiPEPy73rK9lp7YJtE%2BMP7OopRU1MZk%3D&reserved=0
    



More information about the Ip-health mailing list